423 related articles for article (PubMed ID: 33173161)
21. SARS-CoV-2 and Aspergillus section Fumigati coinfection in an immunocompetent patient treated with corticosteroids.
Sasoni N; Rodriguez Müller M; Posse G; González J; Leonardelli F; Garcia-Effron G
Rev Iberoam Micol; 2021; 38(1):16-18. PubMed ID: 33500209
[TBL] [Abstract][Full Text] [Related]
22. COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey.
Breccia M; Piciocchi A; De Stefano V; Finazzi G; Iurlo A; Fazi P; Soddu S; Martino B; Palandri F; Siragusa S; Albano F; Passamonti F; Vignetti M; Vannucchi AM
Leukemia; 2020 Oct; 34(10):2813-2814. PubMed ID: 32843716
[No Abstract] [Full Text] [Related]
23. Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial.
Saiz-Rodríguez M; Peña T; Lázaro L; González Á; Martínez A; Cordero JA; Vicente JT; Richard F; Coma MJ; de Frutos M; Labrador J; Pueyo A
Trials; 2020 Jul; 21(1):632. PubMed ID: 32646502
[TBL] [Abstract][Full Text] [Related]
24. Good response of low-dose steroid in a patient with COVID-19 pneumonia and autoimmune disease.
Chang YY; Wang WH; Ku SW
J Microbiol Immunol Infect; 2021 Oct; 54(5):1001-1002. PubMed ID: 34090821
[No Abstract] [Full Text] [Related]
25. Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial.
Olagunju A; Fowotade A; Olagunoye A; Ojo TO; Adefuye BO; Fagbamigbe AF; Adebiyi AO; Olagunju OI; Ladipo OT; Akinloye A; Adeagbo BA; Onayade A; Bolaji OO; Happi C; Rannard S; Owen A
Trials; 2021 Jan; 22(1):3. PubMed ID: 33397457
[TBL] [Abstract][Full Text] [Related]
26. Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?
Caocci G; La Nasa G
Ann Hematol; 2020 Jul; 99(7):1675-1676. PubMed ID: 32405693
[No Abstract] [Full Text] [Related]
27. Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial.
Vergis N; Phillips R; Cornelius V; Katsarou A; Youngstein T; Cook L; Willicombe M; Pilay C; Shturova T; Almonte M; Charania A; Turner R; Kon OM; Cooke G; Thursz M; Cherlin S; Wason J; Milojkovic D; Innes AJ; Cooper N
Trials; 2021 Apr; 22(1):270. PubMed ID: 33845867
[TBL] [Abstract][Full Text] [Related]
28. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
29. A clinicopathological study of eight patients with COVID-19 pneumonia and a late-onset exanthema.
Herrero-Moyano M; Capusan TM; Andreu-Barasoain M; Alcántara-González J; Ruano-Del Salado M; Sánchez-Largo Uceda ME; Calzado-Villarreal L; Pérez-González Y
J Eur Acad Dermatol Venereol; 2020 Sep; 34(9):e460-e464. PubMed ID: 32426864
[No Abstract] [Full Text] [Related]
30. SARS-CoV-2 Infection in an Adolescent With X-linked Agammaglobulinemia.
Pereira NMD; Heath PT; Doerholt K; Almario-Hernandez AF; Gilmour C; Drysdale SB
Pediatr Infect Dis J; 2021 Dec; 40(12):e472-e474. PubMed ID: 34596628
[TBL] [Abstract][Full Text] [Related]
31. JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis.
Chen CX; Wang JJ; Li H; Yuan LT; Gale RP; Liang Y
Leukemia; 2021 Sep; 35(9):2616-2620. PubMed ID: 33990684
[TBL] [Abstract][Full Text] [Related]
32. Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib.
Saraceni F; Scortechini I; Mancini G; Mariani M; Federici I; Gaetani M; Barbatelli P; Minnucci ML; Bagnarelli P; Olivieri A
Transpl Infect Dis; 2021 Feb; 23(1):e13401. PubMed ID: 32629531
[TBL] [Abstract][Full Text] [Related]
33. Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia.
Tadmor T; Benjamini O; Braester A; Rahav G; Rokach L
Leukemia; 2021 Sep; 35(9):2727-2730. PubMed ID: 34376803
[No Abstract] [Full Text] [Related]
34. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Gottlieb RL; Nirula A; Chen P; Boscia J; Heller B; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Klekotka P; Shen L; Skovronsky DM
JAMA; 2021 Feb; 325(7):632-644. PubMed ID: 33475701
[TBL] [Abstract][Full Text] [Related]
35. Delayed pulmonary abscess following COVID-19 pneumonia: A case report.
Renaud-Picard B; Gallais F; Riou M; Zouzou A; Porzio M; Kessler R
Respir Med Res; 2020 Nov; 78():100776. PubMed ID: 32623310
[No Abstract] [Full Text] [Related]
36. Clinical and radiological findings of adult hospitalized patients with community-acquired pneumonia from SARS-CoV-2 and endemic human coronaviruses.
Baek MS; Cha MJ; Kim MC; Chung JW; Kim WY; Choi H; Choi SH
PLoS One; 2021; 16(1):e0245547. PubMed ID: 33444422
[TBL] [Abstract][Full Text] [Related]
37. Reduction in the rate and improvement in the prognosis of COVID-19 in haematological patients over time.
Cattaneo C; Pagani C; Cancelli V; Imberti L; Roccaro AM; Notarangelo LD; Rossi G
Leukemia; 2021 Feb; 35(2):632-634. PubMed ID: 32770087
[No Abstract] [Full Text] [Related]
38. IFN-α levels in ruxolitinib-treatead Aicardi-Goutières patient during SARS-CoV-2 infection: A case report.
Badolato R; Cattalini M; Scaduto R; Roversi S; Galli J; Ferraro RM; Cortesi M; Orcesi S; Giliani S; Fazzi E
Clin Immunol; 2021 Jun; 227():108743. PubMed ID: 33930555
[No Abstract] [Full Text] [Related]
39. A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial.
Takayama S; Namiki T; Ito T; Arita R; Nakae H; Kobayashi S; Yoshino T; Ishigami T; Tanaka K; Kainuma M; Nochioka K; Takagi A; Mimura M; Yamaguchi T; Ishii T
Trials; 2020 Oct; 21(1):827. PubMed ID: 33008479
[TBL] [Abstract][Full Text] [Related]
40. Clinical characteristics and outcomes of critically ill mechanically ventilated COVID-19 patients receiving interleukin-6 receptor antagonists and corticosteroid therapy: a preliminary report from a multinational registry.
Amer M; Kamel AM; Bawazeer M; Maghrabi K; Butt A; Dahhan T; Kseibi E; Khurshid SM; Abujazar M; Alghunaim R; Rabee M; Abualkhair M; Al-Janoubi A; AlFirm AT; Gajic O; Walkey AJ; Mosier JM; Zabolotskikh IB; Gavidia OY; Teruel SY; Bernstein MA; Boman K; Kumar VK; Bansal V; Kashyap R;
Eur J Med Res; 2021 Oct; 26(1):117. PubMed ID: 34600589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
